Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Rating) in a report published on Monday morning. The brokerage issued a sell rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of NYSE NAVB opened at $0.23 on Monday. The company’s fifty day moving average is $0.25 and its 200-day moving average is $0.50. The stock has a market cap of $7.52 million, a price-to-earnings ratio of -0.41 and a beta of 1.36. Navidea Biopharmaceuticals has a twelve month low of $0.21 and a twelve month high of $1.35.

Navidea Biopharmaceuticals Company Profile

(Get Rating)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

See Also

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.